Enanta Pharmaceuticals Doses First Patient in Phase 2b/3 Trial of Zelicapavir in RSV Infection

MT newswire2026/10/26 12:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

08:00 AM EDT, 10/26/2026 (MT Newswires) -- Enanta Pharmaceuticals (ENTA) said Monday it has dosed the first patient in its global phase 2b/3 trial testing zelicapavir in adults at high risk of severe outcomes from RSV infection. The placebo-controlled trial will evaluate duration of symptoms and hospitalization rate in adult outpatients at least 75 years old with chronic obstructive pulmonary disease or congestive heart failure, the company said. The trial will enroll at least 200 patients in phase 2b and about 660 in phase 3, with topline phase 2b results expected in 2027, Enanta said.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to reports, the trading firm JonesTrading is marketing up to $500 million worth of stock shares on behalf of some investors, at a 3% to 5% premium over the IPO issue price. This indicates that investors are already transferring their anticipated IPO allotted shares before the IPO is officially issued.

华尔街见闻•2026/11/10 23:03